Serine/threonine-protein kinase mTOR · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Serine/threonine-protein kinase mTOR shows late clinical disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 13 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P42345. Start with neoplasm, then reuse UniProt P42345 as the stable protein anchor across project notes and exports.
Start with neoplasm, then reuse UniProt P42345 as the stable protein anchor across project notes and exports.
Serine/threonine-protein kinase mTOR shows late clinical disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 13 linked drugs remain visible in the same block.
Start review with neoplasm because it currently carries late clinical support. Linked drugs include AZD-8055, DACTOLISIB, DS-7423, GEDATOLISIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxySerine/threonine-protein kinase mTOR
Review this target as Serine/threonine-protein kinase mTOR, mapped to UniProt P42345. Sequence length is 2549 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Serine/threonine-protein kinase mTOR as ChEMBL target CHEMBL2842, mapped to UniProt P42345. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Serine/threonine-protein kinase mTOR is the right protein anchor across sources, using UniProt P42345 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why neoplasm is currently framed as late clinical support. It currently carries 13 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Serine/threonine-protein kinase mTOR |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P42345 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Serine/threonine-protein kinase mTOR |
| UniProt Accession | P42345 |
| Component Type | Protein |
| Sequence Length | 2549 aa |
Serine/threonine-protein kinase mTOR
Review this target as Serine/threonine-protein kinase mTOR, mapped to UniProt P42345. Sequence length is 2549 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Serine/threonine-protein kinase mTOR shows late clinical disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.
Start review with neoplasm because it currently carries late clinical support. Linked drugs include AZD-8055, DACTOLISIB, DS-7423, GEDATOLISIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL413 | 10.3 | IC50 | 0.05 | Approved |
| CHEMBL3645910 | 10.15 | IC50 | 0.07 | Preclinical |
| CHEMBL558955 | 10.1 | IC50 | 0.08 | Preclinical |
| CHEMBL3545097 | 10.04 | Kd | 0.092 | Clinical |
| CHEMBL1091714 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL1098245 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL566004 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL566216 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL585480 | 10.0 | IC50 | 0.1 | Preclinical |
| CHEMBL573157 | 9.96 | IC50 | 0.11 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 598 | 4,261 | 7.3 |
| cell-based format | 296 | 407 | 7.4 |
| assay format | 74 | 303 | 7.0 |
| subcellular format | 21 | 1 | 8.2 |
| organism-based format | 5 | 68 | 5.8 |
| protein complex format | 2 | 0 | — |
| tissue-based format | 1 | 1 | 6.7 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 27 | 2 | 7.5 |
| assay format | 6 | 0 | — |
| organism-based format | 4 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 1 | 7.6 |
| single protein format | 1 | 8 | 5.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 3 | 6.2 |